

Juha O Rinne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/655012/publications.pdf>

Version: 2024-02-01

138
papers

8,081
citations

71102

41
h-index

51608

86
g-index

148
all docs

148
docs citations

148
times ranked

11275
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
2	¹¹ C-PiB PET assessment of change in fibrillar amyloid- β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. <i>Lancet Neurology</i> , 2010, 9, 363-372.	10.2	674
3	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	7.4	501
4	A Phase II Trial of Tideglusib in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 75-88.	2.6	363
5	Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. <i>Annals of Neurology</i> , 1989, 26, 47-50.	5.3	285
6	PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease. <i>Stem Cell Reports</i> , 2017, 9, 1885-1897.	4.8	239
7	Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 18.	6.2	208
8	Rate of progression in Parkinson's disease: A ¹⁸ F-fluoro-L-dopa PET study. <i>Movement Disorders</i> , 2001, 16, 608-615.	3.9	201
9	Effects of Working-Memory Training on Striatal Dopamine Release. <i>Science</i> , 2011, 333, 718-718.	12.6	191
10	Decrease in Human Striatal Dopamine D ₂ Receptor Density with Age: A PET Study with [¹¹ C]Raclopride. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 310-314.	4.3	186
11	C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. <i>Synapse</i> , 2009, 63, 907-912.	1.2	156
12	The pedunculopontine nucleus: its role in the genesis of movement disorders. <i>Yonsei Medical Journal</i> , 2000, 41, 167.	2.2	155
13	Sex Differences in Extrastriatal Dopamine D2-Like Receptors in the Human Brain. <i>American Journal of Psychiatry</i> , 2001, 158, 308-311.	7.2	138
14	Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 553-557.	2.2	134
15	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
16	In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand [¹¹ C]-PK11195. <i>Journal of Nuclear Medicine</i> , 2014, 55, 939-944.	5.0	132
17	Choline acetyltransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. <i>Acta Neuropathologica</i> , 2001, 102, 160-166.	7.7	116
18	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 274-284.	0.8	113

#	ARTICLE	IF	CITATIONS
19	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017, 13, 285-295.	0.8	108
20	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β^2 in a multicentre European memory clinic study. <i>Brain</i> , 2016, 139, 2540-2553.	7.6	107
21	Cardiovascular Risk Factors From Childhood and Midlife Cognitive Performance. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2279-2289.	2.8	100
22	Quantification of [¹⁸ F]DPA-714 Binding in the Human Brain: Initial Studies in Healthy Controls and Alzheimer's Disease Patients. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 766-772.	4.3	99
23	[¹⁸ F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β^2 detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. <i>Acta Neuropathologica</i> , 2012, 124, 833-845.	7.7	75
24	Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). <i>Alzheimer's Research and Therapy</i> , 2019, 11, 53.	6.2	75
25	Long-Term Test-Retest Reliability of Striatal and Extrastriatal Dopamine D _{2/3} Receptor Binding: Study with [¹¹ C]Raclopride and High-Resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1199-1205.	4.3	72
26	Reproducibility and Effect of Levodopa on Dopamine Transporter Function Measurements: A [¹⁸ F]CFT PET Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 1604-1609.	4.3	69
27	The Older Finnish Twin Cohort – 45 Years of Follow-up. <i>Twin Research and Human Genetics</i> , 2019, 22, 240-254.	0.6	68
28	PET examination of the monoamine transporter with [¹¹ C]-CIT and [¹¹ C]-CFT in early parkinson's disease. <i>Synapse</i> , 1995, 21, 97-103.	1.2	67
29	Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. <i>American Journal of Human Genetics</i> , 2016, 98, 735-743.	6.2	65
30	Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1646-1651.	5.0	63
31	Interindividual variability and lateralization of μ_4 -opioid receptors in the human brain. <i>NeuroImage</i> , 2020, 217, 116922.	4.2	60
32	Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells. <i>Journal of Neuroinflammation</i> , 2015, 12, 81.	7.2	59
33	Prevalence of the apolipoprotein E μ_4 allele in amyloid β^2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
34	In Vivo PET Imaging Demonstrates Diminished Microglial Activation After Fingolimod Treatment in an Animal Model of Multiple Sclerosis. <i>Journal of Nuclear Medicine</i> , 2015, 56, 305-310.	5.0	57
35	[¹⁸ F]FDOPA and [¹⁸ F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. <i>Synapse</i> , 2001, 40, 193-200.	1.2	54
36	Use of amyloid-PET to determine cutpoints for CSF markers. <i>Neurology</i> , 2016, 86, 50-58.	1.1	54

#	ARTICLE	IF	CITATIONS
37	The Glu318Gly mutation of the presenilin-1 gene does not necessarily cause Alzheimer's disease. <i>Annals of Neurology</i> , 1998, 44, 965-967.	5.3	53
38	Brain energy metabolism and neuroinflammation in ageing APP/PS1-21 mice using longitudinal ¹⁸ F-FDG and ¹⁸ F-DPA-714 PET imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2870-2882.	4.3	53
39	Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation. <i>Neurology</i> , 2018, 90, e1150-e1157.	1.1	53
40	Association Between Childhood-Onset Epilepsy and Amyloid Burden 5 Decades Later. <i>JAMA Neurology</i> , 2017, 74, 583.	9.0	52
41	Microglial activation, white matter tract damage, and disability in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e443.	6.0	51
42	Picture naming deficits in vascular dementia and Alzheimer's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 1997, 19, 126-140.	1.3	46
43	Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, and cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 695-705.	2.6	44
44	Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety. <i>Neuropsychopharmacology</i> , 2020, 45, 1953-1959.	5.4	44
45	Biochemical and clinical effects of Whey protein supplementation in Parkinson's disease: A pilot study. <i>Journal of the Neurological Sciences</i> , 2016, 367, 162-170.	0.6	43
46	Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study. <i>Theranostics</i> , 2021, 11, 6644-6667.	10.0	42
47	Imaging neuroinflammation in multiple sclerosis using TSPO-PET. <i>Clinical and Translational Imaging</i> , 2015, 3, 461-473.	2.1	41
48	Magia: Robust Automated Image Processing and Kinetic Modeling Toolbox for PET Neuroinformatics. <i>Frontiers in Neuroinformatics</i> , 2020, 14, 3.	2.5	41
49	Automated Reference Region Extraction and Population-Based Input Function for Brain [¹¹ C]TMSX PET Image Analyses. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 157-165.	4.3	40
50	Neuroinflammation Appears Early on PET Imaging and Then Plateaus in a Mouse Model of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2018, 59, 509-515.	5.0	40
51	Insulin resistance is associated with poorer verbal fluency performance in women. <i>Diabetologia</i> , 2015, 58, 2545-2553.	6.3	37
52	Brain amyloid load and its associations with cognition and vascular risk factors in FINGER Study. <i>Neurology</i> , 2018, 90, e206-e213.	1.1	36
53	Natalizumab treatment reduces microglial activation in the white matter of the MS brain. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e574.	6.0	34
54	Cortical 11C-PIB Uptake is Associated with Age, APOE Genotype, and Gender in "Healthy Aging". <i>Journal of Alzheimer's Disease</i> , 2014, 41, 193-202.	2.6	33

#	ARTICLE	IF	CITATIONS
55	Synthesis and evaluation of a ¹⁸ F-curcumin derivate for β -amyloid plaque imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2753-2762.	3.0	32
56	Brain Glucose Metabolism in Health, Obesity, and Cognitive Decline—Does Insulin Have Anything to Do with It? A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1532.	2.4	32
57	Radiosynthesis and Preclinical Evaluation of [¹⁸ F]F-DPA, A Novel Pyrazolo[1,5a]pyrimidine Acetamide TSPO Radioligand, in Healthy Sprague Dawley Rats. <i>Molecular Imaging and Biology</i> , 2017, 19, 736-745.	2.6	31
58	Association of Early β -Amyloid Accumulation and Neuroinflammation Measured With [¹¹ C]PBR28 in Elderly Individuals Without Dementia. <i>Neurology</i> , 2021, 96, e1608-e1619.	1.1	30
59	Training working memory updating in Parkinson's disease: A randomised controlled trial. <i>Neuropsychological Rehabilitation</i> , 2020, 30, 673-708.	1.6	28
60	[¹⁸ F]F-DPA for the detection of activated microglia in a mouse model of Alzheimer's disease. <i>Nuclear Medicine and Biology</i> , 2018, 67, 1-9.	0.6	27
61	Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	26
62	Chronic diseases and objectively monitored physical activity profile among aged individuals—a cross-sectional twin cohort study. <i>Annals of Medicine</i> , 2019, 51, 78-87.	3.8	25
63	Striatal 6-[¹⁸ F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: Differing response in relation to presynaptic dopaminergic dysfunction. , 1997, 27, 336-346.		24
64	Imaging of microglial activation in MS using PET: Research use and potential future clinical application. <i>Multiple Sclerosis Journal</i> , 2017, 23, 496-504.	3.0	24
65	Parametric Binding Images of the TSPO Ligand [¹⁸ F]F-DPA-714. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1543-1547.	5.0	23
66	Cognitive Outcome in Childhood-Onset Epilepsy: A Five-Decade Prospective Cohort Study. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 332-340.	1.8	23
67	[¹⁸ F]FMPEP-d2 PET imaging shows age- and genotype-dependent impairments in the availability of cannabinoid receptor 1 in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 69, 199-208.	3.1	23
68	Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 459.	2.4	23
69	Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 606.	2.4	21
70	Increased dopamine release after working-memory updating training: Neurochemical correlates of transfer. <i>Scientific Reports</i> , 2017, 7, 7160.	3.3	20
71	Midlife Insulin Resistance as a Predictor for Late-Life Cognitive Function and Cerebrovascular Lesions. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 215-228.	2.6	20
72	Prospective Flutemetamol Positron Emission Tomography and Histopathology in Normal Pressure Hydrocephalus. <i>Neurodegenerative Diseases</i> , 2014, 13, 237-245.	1.4	18

#	ARTICLE	IF	CITATIONS
73	Long-term leisure-time physical activity and other health habits as predictors of objectively monitored late-life physical activity – A 40-year twin study. <i>Scientific Reports</i> , 2018, 8, 9400.	3.3	18
74	27-Hydroxycholesterol, cognition, and brain imaging markers in the FINGER randomized controlled trial. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 56.	6.2	18
75	Glial Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129.	3.9	18
76	Middle age self-report risk score predicts cognitive functioning and dementia in 20–40 years. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 118-125.	2.4	17
77	Applicability of [¹¹ C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model. <i>Neurobiology of Aging</i> , 2017, 57, 84-94.	3.1	17
78	White Matter Changes on Diffusion Tensor Imaging in the FINGER Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 75-86.	2.6	17
79	Change in CAIDE Dementia Risk Score and Neuroimaging Biomarkers During a 2-Year Multidomain Lifestyle Randomized Controlled Trial: Results of a Post-Hoc Subgroup Analysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1407-1414.	3.6	17
80	Reduced Striatal Dopamine Synthesis Capacity is Associated with Symptoms of Depression in Patients with de novo Unmedicated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 325-329.	2.8	16
81	Midlife Physical Activity and Cognition Later in Life: A Prospective Twin Study. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1303-1317.	2.6	16
82	Brain regional iron contents in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 28-32.	2.2	16
83	Albuminuria and Microalbuminuria as Predictors of Cognitive Performance in a General Population: An 11-Year Follow-Up Study. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 635-648.	2.6	16
84	Comparison of high and low molar activity TSPO tracer [¹⁸ F]F-DPA in a mouse model of Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1012-1020.	4.3	16
85	Objectively measured physical activity profile and cognition in Finnish elderly twins. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 263-271.	3.7	14
86	Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer's disease: a potential early sign of AD. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 37.	6.2	12
87	Brain glucose metabolism and its relation to amyloid load in middle-aged adults with childhood-onset epilepsy. <i>Epilepsy Research</i> , 2017, 137, 69-72.	1.6	11
88	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PIB-PET images and correlation with CSF concentrations of A β species. <i>NeuroImage: Clinical</i> , 2018, 20, 603-610.	2.7	11
89	Domain-specific cognitive effects of white matter pathology in old age, mild cognitive impairment and Alzheimer's disease. <i>Aging, Neuropsychology, and Cognition</i> , 2020, 27, 453-470.	1.3	11
90	Brain β -Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline. <i>American Journal of Neuroradiology</i> , 2019, 40, 80-85.	2.4	10

#	ARTICLE	IF	CITATIONS
91	Visual rating method and tensor-based morphometry in the diagnosis of mild cognitive impairment and Alzheimer's disease: a comparative magnetic resonance imaging study. <i>Acta Radiologica</i> , 2016, 57, 348-355.	1.1	9
92	Cerebral grey matter density is associated with neuroreceptor and neurotransmitter availability: A combined PET and MRI study. <i>NeuroImage</i> , 2021, 235, 117968.	4.2	9
93	Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 123-133.	2.6	8
94	Effect of genotype and age on cerebral [18F]FDG uptake varies between transgenic APPSwe-PS1dE9 and Tg2576 mouse models of Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 5700.	3.3	8
95	Motives for physical activity in older men and women: A twin study using accelerometer-measured physical activity. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2020, 30, 1409-1422.	2.9	8
96	Increased risk for dementia in neurofibromatosis type 1. <i>Genetics in Medicine</i> , 2021, 23, 2219-2222.	2.4	8
97	Education as a moderator of middle-age cardiovascular risk factor-old-age cognition relationships: testing cognitive reserve hypothesis in epidemiological study. <i>Age and Ageing</i> , 2022, 51, .	1.6	8
98	Atlas of type 2 dopamine receptors in the human brain: Age and sex dependent variability in a large PET cohort. <i>NeuroImage</i> , 2022, 255, 119149.	4.2	8
99	SNCA mutation p.Ala53Glu is derived from a common founder in the Finnish population. <i>Neurobiology of Aging</i> , 2017, 50, 168.e5-168.e8.	3.1	7
100	(S)-[18F]THK5117 brain uptake is associated with A β 2 plaques and MAO-B enzyme in a mouse model of Alzheimer's disease. <i>Neuropharmacology</i> , 2021, 196, 108676.	4.1	7
101	Dimethyl fumarate decreases short-term but not long-term inflammation in a focal EAE model of neuroinflammation. <i>EJNMMI Research</i> , 2022, 12, 6.	2.5	7
102	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics. <i>Frontiers in Neurology</i> , 2022, 13, 826423.	2.4	7
103	18 F-labeling syntheses and preclinical evaluation of functionalized nanoliposomes for Alzheimer's disease. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 88, 257-266.	4.0	6
104	Disentangling the Role of Working Memory in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 572037.	3.4	6
105	Mortality in Parkinson's disease is not associated with the severity of early dopaminergic defect. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 894-897.	2.2	5
106	Cognitive Effects of White Matter Pathology in Normal and Pathological Aging. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 489-493.	2.6	5
107	Cessation of anti-VLA-4 therapy in a focal rat model of multiple sclerosis causes an increase in neuroinflammation. <i>EJNMMI Research</i> , 2019, 9, 38.	2.5	4
108	Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 40-44.	2.2	4

#	ARTICLE	IF	CITATIONS
109	Application of the PET ligand [11C]ORM-13070 to examine receptor occupancy by the β -2C-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain. <i>EJNMMI Research</i> , 2020, 10, 152.	2.5	4
110	Positron Emission Tomography in the Differential Diagnosis of Parkinsonism. <i>Journal of Movement Disorders</i> , 2009, 2, 53-57.	1.3	4
111	Insulin-Independent and Dependent Glucose Transporters in Brain Mural Cells in CADASIL. <i>Frontiers in Genetics</i> , 2020, 11, 1022.	2.3	4
112	Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [¹⁸ F]FMPEP. <i>Movement Disorders</i> , 2022, 37, 1673-1682.	3.9	4
113	Drug development for neurodegenerative diseases: role of PET. <i>Annals of Medicine</i> , 1999, 31, 444-449.	3.8	3
114	Longitudinal changes in the brain in mild cognitive impairment: a magnetic resonance imaging study using the visual rating method and tensor-based morphometry. <i>Acta Radiologica</i> , 2018, 59, 973-979.	1.1	3
115	Effects of White Matter Hyperintensities on Verbal Fluency in Healthy Older Adults and MCI/AD. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 614809.	3.4	3
116	Hypermetabolism of Olivary Nuclei in a Patient with Progressive Ataxia and Palatal Tremor. <i>Tremor and Other Hyperkinetic Movements</i> , 2015, 5, 342.	2.0	3
117	Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese. <i>Brain Research</i> , 2016, 1652, 97-102.	2.2	2
118	Oral Glucose Tolerance Test Predicts Episodic Memory Decline: A 10-Year Population-Based Follow-up Study. <i>Diabetes Care</i> , 2021, 44, dc210042.	8.6	2
119	Regional gray matter correlates of memory for emotion-laden words in middle-aged and older adults: A voxel-based morphometry study. <i>PLoS ONE</i> , 2017, 12, e0182541.	2.5	2
120	Differences in brain changes between adults with childhood-onset epilepsy and controls: A prospective population-based study. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 322-331.	2.1	2
121	Effect of APOE ϵ 4 gene dose on regional early neuroinflammation and beta-amyloid deposition in cognitively normal elderly volunteers. <i>Alzheimer's and Dementia</i> , 2020, 16, e043359.	0.8	1
122	Episodic memory and cortical amyloid pathology: PET study in cognitively discordant twin pairs. <i>Neurobiology of Aging</i> , 2021, 108, 122-132.	3.1	1
123	P3-189: DIAGNOSTIC EFFECTIVENESS OF QUANTITATIVE [18F]FLUTEMETAMOL PET IMAGING IN SUBJECTS WITH NORMAL PRESSURE HYDROCEPHALUS USING BIOPSY HISTOPATHOLOGY STANDARD OF TRUTH FOR DETECTION OF FIBRILLAR AMYLOID B. , 2014, 10, P699-P699.		0
124	DT-02-06: Middle age protective score based on self-reported measures predicts dementia status in old age: A population-based study with 28-year follow-up. , 2015, 11, P335-P335.		0
125	P2-422: Insulin Resistance is Associated With a Decline in Verbal Fluency During 11 Years of Follow-up. <i>Alzheimer's and Dementia</i> , 2016, 12, P806.	0.8	0
126	P3-030: White Matter Changes on Diffusion Tensor Imaging in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). , 2016, 12, P828-P828.		0

#	ARTICLE	IF	CITATIONS
127	P3-367: Cognitive Reserve as Indexed by Educational and Occupational Attainment Moderates the Association Between Cardiovascular Disease and Dementia. , 2016, 12, P989-P990.		0
128	Parkinsonian Patients with Striatal Cribiform State Present Rapidly Progressive Axial Parkinsonism. European Neurology, 2017, 78, 119-124.	1.4	0
129	[P3-574]: ASSOCIATIONS OF LEUCOCYTE TELOMERE LENGTH WITH BRAIN MRI AND PIB-PET MEASURES: THE FINGER STUDY. Alzheimer's and Dementia, 2017, 13, P1199.	0.8	0
130	[P3-579]: IMPACT OF BASELINE BRAIN MRI MEASURES ON COGNITIVE EFFECTS OF A MULTIDOMAIN INTERVENTION: THE FINGER RANDOMIZED CONTROLLED TRIAL. Alzheimer's and Dementia, 2017, 13, P1202.	0.8	0
131	P2-605: EDUCATION, MIDDLE-AGE BODY MASS INDEX AND OLD AGE COGNITIVE FUNCTIONING: A POPULATION-BASED QUASI-EXPERIMENTAL TWIN STUDY. Alzheimer's and Dementia, 2018, 14, P971.	0.8	0
132	O2-03-01: MIDLIFE INSULIN RESISTANCE AND LATE-LIFE COGNITION, BRAIN AMYLOID ACCUMULATION, AND CEREBROVASCULAR LESIONS. Alzheimer's and Dementia, 2018, 14, P613.	0.8	0
133	Change in CAIDE dementia risk score and neuroimaging biomarkers during a 2-year multidomain lifestyle randomized controlled trial. Alzheimer's and Dementia, 2020, 16, e040879.	0.8	0
134	Brain beta-amyloid in twin pairs discordant for episodic memory performance. Alzheimer's and Dementia, 2020, 16, e045741.	0.8	0
135	[P3-170]: HUMAN IPSC-DERIVED ALZHEIMER'S DISEASE ASTROCYTES RECAPITULATE DISEASE-RELATED PHENOTYPES. Alzheimer's and Dementia, 2017, 13, P999.	0.8	0
136	Chronic low-grade inflammation predicts greater decline in verbal fluency and word-list learning on 10 years' follow-up. Alzheimer's and Dementia, 2021, 17, .	0.8	0
137	Brain amyloid load and cognitive trajectories in older individuals at risk for dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
138	Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy. Movement Disorders, 2022, 37, 1776-1778.	3.9	0